Method of reducing neuronal microtubule binding protein tau (tau) levels
AssigneeAdaerata, Limited Partnership
InventorsMichel CAYOUETTE, Marine LACOMME
Life of this patent
Estimating the term…
Loading patent…
AssigneeAdaerata, Limited Partnership
InventorsMichel CAYOUETTE, Marine LACOMME
Estimating the term…
There is provided a method of reducing neuronal microtubule binding protein Tau (Tau) levels, promoting neuronal Tau degradation and/or promoting neuronal survival, in a subject in need thereof comprising contacting the subjects neurons with an effective amount of an agent that increases a long phosphotyrosine-binding (PTB) Numb isoform expression and/or activity, whereby neural Tau levels is reduced in the presence of the agent, the neuronal Tau degradation is promoted and/or the neuronal survival is promoted as compared to in the absence thereof. Also provided are methods of stratification based on PTB Numb isoform expression and/or activity of the subjects and compositions and kits for applying the methods.
A method of reducing neuronal microtubule binding protein Tau (Tau) levels, promoting neuronal Tau degradation and/or promoting neuronal survival, in a subject in need thereof comprising contacting the subject's neurons with an effective amount of an agent that increases a long phosphotyrosine-binding (PTB) Numb isoform expression and/or activity, whereby neural Tau levels is reduced in the presence of the agent, the neuronal Tau degradation is promoted and/or the neuronal survival is promoted as compared to in the absence thereof.
A method for stratifying a subject having a pathological condition associated with toxic intraneuronal Tau accumulation, comprising detecting a long phosphotyrosine-binding (PTB) Numb isoform expression and/or activity in the subject's neurons, wherein said detecting enables the stratification of the subject, preferably wherein when a reduced long PTB Numb isoform expression and/or activity is detected as compared to a reference long PTB Numb isoform expression and/or activity, the subject is included in a clinical trial for an agent that increases the long PTB Numb isoform expression and/or activity.
A composition comprising (a) an agent that increases neuronal long phosphotyrosine-binding (PTB) Numb isoform expression and/or activity;
A kit or package comprising (A) (a) an agent that increases neuronal long phosphotyrosine-binding (PTB) Numb isoform expression and/or activity;
(canceled)
Dependencies are inferred from the claim text.